A Phase 2 interventional study of SPC1001 Low and SPC5002 in Hypertension (HTN), NYHA Class III Heart Failure and NYHA Class IV Heart Failure, sponsored by Shin Poong Pharmaceutical Co. Ltd.. Enrolling by invitation at 1 site in South Korea. Open to participants aged 19 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-07-14.
Sponsored by Shin Poong Pharmaceutical Co. Ltd. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 353 studies in Hypertension with a site in Korea, Republic of — 31 open to participants now, 41 under way, 11 of them phase 3. Hypertension · Korea, Republic of.
Among the 353 studies in Hypertension with a site in Korea, Republic of, this one is the 70th largest by planned enrollment of the 304 interventional ones that give a count, is one of 15 that started in 2024, is one of 21 in phase 2, reaches primary completion later than 14 of the 40 other live ones, and was the 330th registered.
6,128 studies on the registry are indexed under Hypertension; 911 are open to participants now.
Browse Hypertension studies →31 of the 353 studies in Hypertension with a site in Korea, Republic of are open now. Recruiting first, the newest first:
Korea United Pharm. Inc. · Sites in Korea, Republic of
Ages 19–54 · Healthy volunteers
Hanmi Pharmaceutical Company Limited · Sites in Korea, Republic of
Hanlim Pharm. Co., Ltd. · Sites in Korea, Republic of
Ages 19+
Keimyung University Dongsan Medical Center · Sites in Korea, Republic of
Ages 19+
Korea University Anam Hospital · Sites in Korea, Republic of
Ages 19+
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 556 Hypertension studies recruiting now, 262 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 137 take healthy volunteers.
This study: 19 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
353 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 102 · Phase 2 22 · Phase 3 93 · Phase 4 60
First in 2003; this study’s year is marked. 15 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 252 is above the median of 100 across 4,585 interventional studies indexed under Hypertension.
Median enrollment 110 across the 304 interventional studies, 2,000 across the 47 observational. Of the 277 that completed or were terminated, 41 (15%) have results posted.
This tab as a report to print or save as PDF → With an account.
283 of 353 have an industry lead sponsor. The 10 most frequent:
Shin Poong Pharmaceutical Co. Ltd. is the lead sponsor of 27 studies on the registry; 3 are open to participants now.
Shin Poong Pharmaceutical Co. Ltd. has 3 studies filed under Hypertension — fewer than ten, so there is no comparison to draw.
5 of the studies in Hypertension with a site in Korea, Republic of that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03683186Phase 3United TherapeuticsA Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension | 2026-12 |
| NCT07660796Phase 3Hanmi Pharmaceutical Company LimitedA Study to Evaluate Efficacy and Safety of HCP1803-4 in Patients With Essential Hypertension | 2027-10-30 |
| NCT07901114AJU Pharm Co., Ltd.A Bioequivalence and Safety Study of AJU-C719 and C719R in Healthy Adult Volunteers | 2026-12 |
| NCT07465549Korea University Anam HospitalCART BP Pro-Guided Blood Pressure Management for Uncontrolled Hypertension | 2026-12-31 |
| NCT07784621Huons Co., Ltd.A Phase 1 Clinical Trial to Evaluate the Safety and the Pharmacokinetic Drug-Drug Interaction Between HUC2A-752-A and HUC2A-752-B in Healthy Adults | 2027-02 |
Add all 5 to your calendar (.ics) → With an account.
Among the 353 studies in Hypertension with a site in Korea, Republic of, from their registry updates:
This tab as a report to print or save as PDF → With an account.
- Objective: This study aims to evaluate the safety and efficacy of the fixed-dose triple combination therapy (SPC1001 Low) of candesartan, amlodipine, and indapamide in adult patients with essential hypertension compared to dual-component therapies of each ingredient for 8 weeks. Additionally, it seeks to confirm the contribution of each component at low doses.
- Inclusion Criteria: Men and women aged 19 to 75 years whose blood pressure measured at the screening visit meets the following criteria.
- Exclusion Criteria: Patients whose blood pressure measured at the screening and randomization visits meets the criteria of MSSBP ≥180 mmHg or MSDBP ≥110 mmHg, among other conditions.
- Methods: This study is a multicenter, randomized, double-blind, parallel-group, phase 2b clinical trial to evaluate the safety and efficacy of the investigational drug after 8 weeks of administration.
Screening assessments will be conducted within 4 weeks prior to randomization, and patients who meet the inclusion and exclusion criteria at the screening visit will be enrolled in the study after providing informed consent. These participants will undergo a 2-week run-in period during which they will take a placebo and participate in a lifestyle modification program.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
low-dose combination therapy
Drug: SPC1001 Low
low-dose combination therapy
Drug: SPC1001 Low · Drug: SPC5002
low-dose combination therapy
Drug: SPC1001 Low · Drug: SPC5003
low-dose combination therapy
Drug: SPC1001 Low · Drug: SPC5004
low-dose combination therapy
low-dose combination therapy
low-dose combination therapy
low-dose combination therapy
The primary endpoint was determined by evaluating how mean sitting systolic blood pressure varied between the baseline measurement and week 8
Time frame: change in MSSBP from baseline at week 8
Plan to share: Yes — It is planned to be publicly available in the form of a future journal submission
Supporting information: Study protocol
No publications or documents are linked to this record.
Started Dec 2024 (actual). Primary completion is estimated for Dec 2025, 12 months after the start.
Of 56 industry-sponsored phase 2 interventional studies under Hypertension, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 22. This study's planned 12 months is below that.
Counting every sponsor, half of 110 studies reached it within 25 months; a quarter within 11 and three quarters within 56.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Shin Poong Pharmaceutical Co. Ltd. →